FDA Clearance Tracker · P250025
TorEx Lung Perfusion System
Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jul 15, 2026
Approved
Time to decision
373 days
Received Jul 7, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P250025
- Device name
- TorEx Lung Perfusion System
- Applicant
- Traferox Technologies, Inc.
- Applicant location
- Mississauga
- Received
- Jul 7, 2025
- Decided
- Jul 15, 2026
- Decision
- Approved
- Supplements
- 2 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Normothermic preservation system for transplantation of initially unacceptable donor lungs (PHO)
- Device class
- Class III
- Specialty
- GI, Urology & Nephrology
FDA's approval statement
As written in FDA's record.
The TorEx Lung Perfusion System is indicated for use in continuous normothermic machine perfusion of donor lungs, initially deemed unsuitable for transplantation, during which time the ex vivo function of the lungs can be reassessed for transplantation in adults. The TorEx Lung Perfusion System includes a mobile cart with embedded software, single-use sterile Organ Chamber and Cannulae set and is used with TorEx Lung Perfusate solution to perform ex vivo lung perfusion for up to 6 hours.Note: The TorEx System is used to evaluate the quality of donated lungs, but the final determination of the suitability of the lungs for transplant remains with the transplanting surgeon.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PHO. The earliest in FDA's data is P180014, decided Apr 26, 2019.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Traferox Technologies, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261913 · Decided Sep 16, 2026 · 100 days after receipt
Device type: System And Accessories, Isolated Heart, Transport And Preservation (MSB) · GI, Urology & Nephrology
K260456 · Decided Jun 1, 2026 · 110 days after receipt
Device type: System, Perfusion, Kidney (KDN) · GI, Urology & Nephrology
K243870 · Decided May 1, 2025 · 135 days after receipt
Device type: System, Perfusion, Kidney (KDN) · GI, Urology & Nephrology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.